Japanese company profile · 4592

SanBio Company Limited

English company name recorded in Japan's EDINET filer data.

Original Japanese company name: サンバイオ株式会社

Name follows the English name recorded in EDINET filer data. English company name source

FY2025 · fiscal year ended January 2026Latest filing date: 2026-04-20

What does this company do?

What does this company do?

In its FY2025 public filing, SanBio Company Limited reports Allogeneic Stem Cell Therapy Business. The page shows business-level revenue and profit where the source disclosures support comparison.

Not disclosed or not safely comparable in the available filings.

FY2025 · fiscal year ended January 2026 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
—
FY2025 · fiscal year ended January 2026
Operating profit
−¥3.79B ↗
FY2025 · fiscal year ended January 2026
Comparable margin
—
FY2025 · fiscal year ended January 2026

JGAAP · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
4592
EDINET code
E31382
Corporate number
6010601044067
Listing status
Listed
Industry (EDINET filer classification)
Pharmaceuticals

Location and fiscal year

Headquarters
東京都中央区 · As filed in Japanese
Latest fiscal year
FY2025
Accounting standard
JGAAP
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
33 people (FY2025)
Employees (non-consolidated)
33 people (FY2025)
Capital stock
JPY 8.4 billion (FY2025)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

FY2025 · fiscal year ended January 2026 · Business Sales Operating profit
BusinessShare of company salesOperating profit
Allogeneic Stem Cell Therapy Business—−¥3.79B ↗

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended January 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company operating profit

JGAAP · Consolidated
  1. FY202183.8−¥6.62B
  2. FY2022100.0−¥7.9B
  3. FY202357.5−¥4.54B
  4. FY202444.5−¥3.52B
  5. FY202548.0−¥3.79B

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

What has changed?

What has changed?

Not disclosed or not safely comparable in the available filings.

What is growing?

What is growing?

No comparable reported revenue growth is available.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth—
    No comparable data
  • Profitability—
    No comparable data
  • Business concentration—
    No comparable data
  • Business change—
    No comparable data
  • Cash generation—
    No comparable data
  • Growth persistence—
    No comparable data

Next

Ask about this company

Source

Public filing

FY2025 · fiscal year ended January 2026

The source document may be in Japanese.

Filing ID: S100XZTW

View original filing ↗

根拠となる資料